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Abstract: Immune checkpoint inhibition represents an important therapeutic option for advanced
melanoma patients. Results from clinical studies have shown that treatment with the PD-1 inhibitors
Pembrolizumab and Nivolumab provides improved response and survival rates. Moreover, combining
Nivolumab with the CTLA-4 inhibitor Ipilimumab is superior to the respective monotherapies.
However, use of these immunotherapies is frequently associated with, sometimes life-threatening,
immune-related adverse events. Thus, more evidence-based studies are required to characterize
the underlying mechanisms, towards more effective clinical management and treatment monitoring.
Our study examines two sets of public adverse event data coming from FAERS and VigiBase,
each with more than two thousand melanoma patients treated with Pembrolizumab. Standard
disproportionality metrics are utilized to characterize the safety of Pembrolizumab and its reaction
profile is compared to those of the widely used Ipilimumab and Nivolumab based on melanoma
cases that report only one of them. Our results confirm known toxicological considerations for
their related and distinct side-effect profiles and highlight specific immune-related adverse reactions.
Our retrospective computational analysis includes more patients than examined in other studies
and relies on evidence coming from public pharmacovigilance data that contain safety reports from
clinical and controlled studies as well as reports of suspected adverse events coming from real-world
post-marketing setting. Despite these informative insights, more prospective studies are necessary to
fully characterize the efficacy of these agents.
Keywords: Pembrolizumab; melanoma; immune checkpoint inhibitors; adverse events; FDA’s
Adverse Event Reporting System (FAERS); VigiBase; pharmacoepidemiology; data mining
1. Introduction
The discovery of immune checkpoints and their role in anti-tumor immunity has revolutionized
treatment of metastatic melanoma. The key targets of immune checkpoint inhibition include the
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein 1 (PD-1),
both of which are expressed by T cells. Binding of CTLA-4 to CD80, which is expressed by antigen
presenting cells, impairs T cell activation, whereas binding of PD-1 to PD-L1, which is expressed
by epithelial cells, immune cells, and tumor cells, induces anergy and exhaustion of the activated T
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cell [1–3]. Thus, the immune checkpoint blockade enhances anti-tumor immunity by increasing T cell
activation and preventing their inhibition [4].
Ipilimumab, a monoclonal antibody targeting CTLA-4, was the first checkpoint inhibitor that in
patients with advanced melanoma demonstrated an improvement in overall survival (OS). In 2011,
it was approved by the United States (US) Food and Drug Administration (FDA) for the treatment of
unresectable or metastatic melanoma [5]. A few years later, trials with antibodies inhibiting the PD-1
pathway demonstrated superiority to chemotherapy in Ipilimumab-refractory melanomas, resulting
in the approval of Pembrolizumab and Nivolumab for the treatment of refractory unresectable or
metastatic melanoma in 2014 [6–10]. Additionally, Pembrolizumab was shown to improve OS, response
rate and progression-free survival (PFS) compared to Ipilimumab in patients with previously untreated
advanced melanoma in the randomized, controlled, phase 3 KEYNOTE-006 study [11,12]. Moreover,
superiority of Pembrolizumab was confirmed by the results of the recent long-term five-year follow up
analysis of patients within this study, revealing median OS of 32.7 months for patients that received
Pembrolizumab compared to 15.9 months for patients treated with Ipilimumab [13]. Furthermore,
given the non-redundant functions of CTLA-4 and PD-1, the rationale to combine anti-CTLA-4 and
anti-PD-1 antibodies was tested in the CheckMate 067 trial. Indeed, the combination of Nivolumab
with Ipilimumab was superior to Ipilimumab and to Nivolumab monotherapy, with PFS of 11.5, 2.9,
and 6.5 months, respectively [14].
According to the positive results from these studies, treatment with anti-PD-1 antibodies—as
mono- or combination-therapy with Ipilimumab—is nowadays a major therapeutic option for advanced
melanoma patients with good performance status [15]. However, despite the success of immune
checkpoint inhibitors (ICI) in melanoma treatment, approximately 40% to 45% of patients experience
no response to therapy. Moreover, administration of these agents is associated with the emergence
of a ‘new class’ of side effects, collectively referred to as immune-related adverse events (irAEs).
These cumulative, dose-dependent, and sometimes life-threatening immune-mediated toxicities can
theoretically affect any organ and are of inflammatory character [16], thereby reflecting the immune
checkpoints’ role in regulating adaptive immunity. In patients treated with ICI monotherapies, reported
incidences of any grade irAEs range from 15% to 90% [17] and mainly affect the gastrointestinal tract,
the liver, the endocrine glands, and the skin [16]. Nonetheless, depending on the type of inhibitor,
some irAEs are more frequently observed than others [18], with lower rates of high-grade irAEs
among anti-PD-1 antibodies compared to anti-CTLA-4 antibodies. Importantly, as the combination of
anti-PD-1 and anti-CTLA-4 leads to a more enhanced immune activation, the frequency of high-grade
irAEs for the combination therapy is higher than for either monotherapy [14,19].
Early recognition of these irAEs is very important and the discontinuation of immunotherapy
and administration of corticosteroids is recommended for successful management [20]. However,
the biomolecular landscape underlying ICI therapy is not yet fully characterized and biomarkers are
necessary for predicting response, resistance and/or toxicity in a systematic way. Since the effective
management of irAEs relies mainly on their early recognition [21,22], several recent efforts emphasize
the need for more evidence-based data and for the identification and characterization of molecular
biomarkers and the genomic correlates of ICI response and irAE toxicities [23–28].
The aim of our study is to utilize real world evidence to provide additional insights to these
profiling efforts of ICIs, and of Pembrolizumab in particular, in the context of melanoma treatment.
We, therefore, searched for sources of accessible clinical phenotype data, such as adverse events (AEs),
and summarized a body of data encompassing more patients than examined in other clinical trials or
translational studies reported thus far. For our analyses, we relied on data coming from two different
AE reporting systems (AERS).
Specifically, we processed AE data from the US FDA AERS (FAERS)—including the legacy AERS
(LAERS) data—and the VigiBase repositories. FAERS contains AE reports, medication error reports
and product quality complaints resulting in AEs that were submitted to the FDA. This computerized
information system is designed to support the US FDA’s post-marketing safety surveillance program.
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VigiBase is maintained by the World Health Organization (WHO) and contains global individual case
safety reports submitted by the participating member states enrolled under the WHO’s international
drug monitoring program. FAERS and EudraVigilance from the European Medicine’s Agency constitute
the main AE reporting management and evaluation systems in the US and Europe, respectively, while
VigiBase is the single largest drug safety data repository in the world. Our findings are intended
to contribute to the emergent knowledge about irAE’s and ultimately facilitate more informed ICI
therapy monitoring.
2. Materials and Methods
To examine the safety of Pembrolizumab in the treatment of melanoma, we reviewed public AE
patient data extracted from the FAERS and VigiBase repositories. The datasets included AE data
released for 2017Q2 by FAERS and for 2018Q2 by VigiBase. Finally, we characterized the safety of
Pembrolizumab by examining AE information as observed in those datasets for melanoma patients.
Figure 1 summarizes our approach.
Data	genera)on	
(PRR,	Fisher’s	exact	test)	
Therapeu)c	agents	
(drug	products,	treatments,	co-medica)ons)	
Outcomes	
(death,	hospitaliza)on,	disability,	life-threatening)	
Indica)ons	
(diseases	and	co-morbidi)es)	
Seriousness	
(applies	to	VigiBase	only)	
Data	Integra)on	
(processing,	mapping)	
Co-medica)on	subgroups	
(too	few	cases	for	co-administra)on	analysis)	
Comparison	of	monotherapies	
REACTIONS 
(symptoms) 
Immune checkpoint 
inhibitors 
Pembrolizumab 
Ipilimumab 
Nivolumab 
Cohorts: (alone) 
Collec&on	of	adverse	events	
(Pembrolizumab	in	Melanoma)	
Number	of	pa&ent	cases	per	dataset	
Real world data
Drug	names	and	MedDRA	hierarchy	
(medica)on	synonyms	and	hierachy	‘preferred	
terms’)	
Adverse	events	
(side-effects,	adverse	reac)ons)	
FAERS	
VigiBase	
Pembrolizumab	 Melanoma	
FAERS	
5896	AEs		
2291	AEs		
VigiBase	
7825	AEs	
2507	AEs	
	Pembrolizumab			
Total:	
In	Melanomas:		
OVERALL	SAFETY	PROFILING	
(adverse	reac)ons	and	pa)ent	demographics)	
Side	effects	
(reac)ons	coded	in	MedDRA	hierarchy	terms)	
TOP REACTION 
CATEGORIES 
Skin 
Thyroid 
Blood 
Hepatic 
Gastrointenstinal 
Diabetes 
Respiratory 
Cardiac 
AE
	d
at
a	
co
lle
c&
on
		
Figure 1. Synopsis of our study: To review adverse events (AEs) related to the therapy of melanoma
patients with Pembrolizumab, we integrated and standardized AE data from two public repositories
(FAERS and VigiBase). From each repository, we extracted a separate cohort of AEs that contained
melanoma patient cases treated with Pembrolizumab. Using disproportionality metrics, these cohorts
were retrospectively characterized with respect to demographics, outcomes, side effects and adverse
reactions reported for those patients. In addition, we report on reaction classes listed in FAERS AEs
that mention only key ICIs (namely, Ipilimumab, Nivolumab, and Pembrolizumab), without any other
co-medications. Last, we expect that our findings as observed in these datasets add to the combined
efforts to more effectively monitor and react on irAEs.
2.1. Adverse Event Data Integration
We processed 7.9 million cases (9.5 million reports) from the publicly available FAERS data set
and 17 million case reports from VigiBase. Both datasets contain de-identified AE patient data and are
similar in that they hold records with information about the patients’ drug therapies, the indications
for those drugs (disease or condition), and the observed reactions and outcomes (e.g., “death” or
“hospitalization”) reported in these AEs.
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One challenge in the computational processing of data from FAERS is the unambiguous
identification of the therapeutic agents relevant to an AE that may be submitted by reporters in
free text descriptions (e.g., “PEMBROLIZUMAB, 25 MG/ML”). While such names may be easily
understandable by humans, they may also contain spelling and typographical errors, language
variations, multiple medications in one phrase, as well as irrelevant terms. To resolve such ambiguities
introduced by the non-standardized use of drug names [29], FAERS free-text medication descriptions
were consolidated and matched to standardized drug synonyms compiled from DrugBank and
PubChem records [30]. In VigiBase, the medications reported for each AE are structured in a different
way, organized by drug product name and ingredient substances.
In comparison, reactions are coded by both datasets in terms from the Medical Dictionary for
Regulatory Activities (MedDRA) and they were analyzed at the Preferred Term (PT) level of the
hierarchy (i.e., MedDRA Level 4 descriptions).
2.2. Definition of Cohorts
We identified 5896 and 7825 AE patient cases from FAERS and VigiBase, respectively, that referred
to treatment with Pembrolizumab in any disease. These AEs were defined as FAERS cases that were
annotated with the ‘Pembrolizumab’ drug record, or as VigiBase cases with product (drug) names
mentioning ‘Pembrolizumab’, ‘Keytruda’, or ‘Lambrolizumab’. Using these AEs we searched for
melanoma-specific subsets, and defined the two main cohorts that were analyzed:
• FAERS PembroM: 2291 AE cases from FAERS of melanoma patients treated with Pembrolizumab.
• VigiBase PembroM: 2507 AE cases from VigiBase of melanoma patients treated with Pembrolizumab.
The two sets (FAERS PembroM and VigiBase PembroM) were processed separately, as VigiBase
contains AEs that are also reported in FAERS. Each cohort was examined with respect to reported
demographics, drugs, indications, reactions, and outcomes. Melanoma cases were defined to be those for
which reported indications linked to the MedDRA hierarchy term ‘Skin melanomas (excluding ocular)’,
such as ‘MALIGNANT MELANOMA’, ‘METASTATIC MALIGNANT MELANOMA’, or ‘MALIGNANT
MELANOMA STAGE IV’.
Both cohorts were also examined for reactions mentioned in AEs of melanoma patient cases
reporting Pembrolizumab as single treatment. These AE subsets were named ‘Pembrolizumab (alone)’.
2.3. Statistical Characterization
For the statistical characterization of the cohorts, we utilized the proportional reporting ratio
(PRR) score, an established measure of disproportionality in pharmacovigilance [31,32] In our analysis,
PRR was defined as the value of a(c + d)/c(a + b) from the following contingency matrix (1).
AE Cases Event (E) Not E Totals
Cohort a b a + b
Not Cohort c d c + d
Totals a + c b + d N = a + b + c + d
An event E may represent the occurrence of reaction(s), drug(s), indication(s), or of patient
outcome(s) in the AEs of each inspected Cohort, e.g., FAERS PembroM or VigiBase PembroM.
To systemize the calculations, each cohort’s AEs were compared against the whole set of remaining
cases from the respective dataset, FAERS or VigiBase. This means that the comparative ‘Not Cohort’
background contained all other AEs from each repository. For instance, in the case of the PembroM
cohorts, the background may include AEs that contain other melanoma cases or cases that may have
reported Pembrolizumab but not both melanoma and Pembrolizumab, because these were included in
the PembroM cohort by definition. In turn, this may have resulted in less strong signals per event E
in each cohort but more specific. Last, we also considered statistical significance be indicated by a
Fisher’s exact test p-value lower than 5% (i.e., when p-value < 0.05).
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2.4. Data Availability
The Supplementary file lists results for the FAERS PembroM and the VigiBase PembroM cohorts.
The file summarizes also demographic information, as well as gender distribution for each reaction,
as observed in each of these two cohorts. Last, the supplementary file includes observed data for each
reaction reported in the examined ‘Pembrolizumab (alone)’ cohorts, too.
3. Results
The data extracted from FAERS and VigiBase are complementary although there is some degree
of overlap. Figure 2 highlights some such examples.
One main difficulty that regulatory authorities face when gathering AE safety data is the systematic
and consistent representation of suspected AE case reports that may come with a variety of detail,
forms and quality. This may change over time and may be due to a multitude of different circumstances.
In turn, features such as age or gender may be missing or highlighted as ‘unknown’ (Figure 2b,c)
as well as other important clinical information (e.g., dosage, administration route, or duration of
symptoms) may be sparse or even unavailable. These collection and reporter/submitter implications
are aspects that each spontaneous repository cannot effectively control and handles them similarly in
scope, but also differently in terms of chosen data representations or levels of abstraction. For example,
VigiBase provides annotations on the ‘report type’ (Figure 2d) whereas FAERS on the ‘reporter’s
occupation’ (Figure 2e). The suspected drug’s ‘role’ is handled somewhat differently (Figure 2f,g) in
that FAERS specifies whether a reported drug was ‘primary’ or ‘secondary’ suspect, whenever such
information is available.
This is important information to consider as in our study several cases were dated prior to
Pembrolizumab’s approval and approximately up to 36% of VigiBase PembroM cases were based
on reports annotated as ‘coming from studies’. It is reasonable to assume that patients evaluated in
some of these cases were enrolled in clinical trials, closely controlled, and followed using determined
protocols and intensive follow-up regimens, but this (or which ones exactly) cannot be confirmed
from these data alone. Therefore, we did not exclude them from our analysis and handled them
uniformly with other real-world post-marketing data, occurring outside controlled and/or clinical
trial environments.
Further complications may rise when dealing with AE data considering that for some cases multiple
reports may be available over time, sometimes duplicates, and sometimes with conflicting information.
Such aspects are tackled by each AERS internally, and are very difficult to handle by examining only
the publicly available, de-identified data. However, some such ‘discrepancies’ may be explicable,
for example due to the fact that one drug may be assigned different ‘roles’ (e.g., suspect or concomitant)
for the same AE (depending on which observed reaction is referred to each time), or because patient-case
information may be updated (or corrected) with follow-up reports. In that respect, FAERS and VigiBase
handle their data somewhat differently, partially attributed to FAERS receiving sometimes multiple
reports for the same case from different submitters whereas VigiBase gathers individual safety records
directly from national authorities, including content coming from FAERS.
To avoid processing the same cases multiple times, in our study we analyze and present results
for each PembroM cohort separately (once for FAERS and once for VigiBase). Each shared event is
therefore counted only once in each cohort, and individual data set characteristics and intricacies
(complications and advantages) were neither combined nor compromised.
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3.1. Overview of the PemboM Cohorts
In total, our AE dataset held 2291 FAERS cases (FAERS PembroM cohort) and 2507 VigiBase cases
(VigiBase PembroM cohort) of melanoma patients treated with Pembrolizumab. Figure 2 summarizes
key demographic characteristic of these c horts. Among these, 61.2% of the FAERS cohort (1402 AEs)
and 66.2% of the VigiBase cohort (1660 AEs) report d only Pembrolizumab and no other drugs.
We named these (sub-) cohorts ‘Pembrolizumab (alone)’.
Furthermore, representation of other ICIs in the PembroM cohorts was sparse—Ipilimumab was
mentioned in 114 FAERS and in 91 VigiBase AEs (in 59 AEs with product name ‘Ipilimumab’ and in 32
as ‘Yervoy’), Atezolizumab was mentioned in three FAERS and in three VigiBase AEs (in two cases
with product name ‘Atezolizumab’ and in one as ‘Tecentriq’), whereas Nivolumab was reported in
nineteen FAERS and in 23 VigiBase (sixteen times as ‘Nivolumab’ and seven as ‘Opdivo’) cases.
Among the most frequent non-melanoma related co-morbidities reported in the two PembroM
cohorts, there were several terms that referred to the general physical condition of the patients in
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addition to very specific and irAE-related symptoms. Characteristically, the twenty most frequent
non-melanoma-related indications mentioned in either of the two cohorts included the following
MedDRA PTs: ‘hypertension’, ‘pain’, ‘hypothyroidism’, ‘prophylaxis’, ‘constipation’, ‘product used
for unknown indication’, ‘routine health maintenance’, ‘nausea’, ‘gastroesophageal reflux disease’,
‘anxiety’, ‘diabetes mellitus’, ‘hypercholesterolaemia’, ‘pruritus’, ‘insomnia’, ‘depression’, ‘rash’,
‘hyperlipidaemia’, ‘diarrhoea’, ‘arthralgia’, ‘cough’, ‘hypertension arterial’, ‘atrial fibrillation’.
Melanoma-related indications included a variety of terms, the most frequent ones being
‘melanoma’, ‘metastatic melanoma’, ‘metastatic malignant melanoma’, ‘malignant melanoma stage iv’,
‘malignant melanoma stage iii’, and ‘melanoma recurrent’. While this suggests that many patients
suffered severe melanoma conditions, in the absence of additional (clinical or historical) data it could
not be clarified whether (or which) PembroM cohort cases possibly came from the treatment of
non-resectable advanced melanoma or from resected melanoma cases that were adjuvantly treated.
The term ‘adjuvant therapy’ was reported only once in each cohort, possibly reflecting the same case.
Overall, the FAERS PembroM cohort captured more cases with severe patient outcomes (death,
hospitalization, life-threatening, disability/incapacitating) than the VigiBase PembroM cohort, and
70.2% of the latter cohort’s cases were explicitly annotated as ‘serious’ (1760 AEs).
3.2. Adverse Event Profiling
We extracted side effect profiles for the two PembroM cohorts by summarizing adverse reactions
described in MedDRA PTs (i.e., level 4 terms) that were reported in FAERS and VigiBase. The following
PTs were not considered, whenever mentioned: ’Adverse event’, ‘Death’, ‘Disease progression’,
‘Inappropriate schedule of drug administration’, ‘Malignant neoplasm progression’, ‘Metastatic
malignant melanoma’, ‘Metastases to central nervous system’, ‘Malignant melanoma’, ‘Toxicity to
various agents’, ‘Therapy non-responder’, ‘Therapy partial responder’.
The two datasets were consistent with respect to the types of adverse reactions they contained.
Table 1 juxtaposes occurrence of reactions that were mentioned in both PembroM cohorts with the
same MedDRA PTs, while Table 2 summarizes our findings altogether in groups of key organ/system
categories and denotes which PembroM cohort they were derived from.
Overall, our analysis could re-capitulate several MedDRA PT reactions that likely reflected irAEs,
among which some with high PRR signals (>5), such as:
• ‘Hypophysitis’ (PRRs: FAERS = 267.82; VigiBase = 308.83) and ‘Adrenal insufficiency’ (PRR:
FAERS = 28.10; VigiBase = 47.47)
• ‘Vitiligo’ (PRRs: FAERS = 166.64; VigiBase = 373.83), ‘Pemphigoid’ (PRRs: FAERS = 24.48; VigiBase
= 53.54), and ‘Rash maculo-papular’ (PRR: FAERS = 9.53)
• ‘Autoimmune colitis’ (PRR: VigiBase = 565.03) and ‘Colitis’ (PRRs: FAERS = 35.8; VigiBase = 22.1)
• ‘Thyroiditis’ (PRRs: FAERS = 42.42; VigiBase = 81.45), ‘Hypothyroidism’ (PRRs: FAERS = 11.22;
VigiBase = 30.35), ‘Hyperthyroidism’ (PRRs: FAERS = 7.16; VigiBase = 23.94), and ‘Thyroid
disorder’ (PRRs: FAERS = 5.38; VigiBase = 9.46)
• ‘Autoimmune hepatitis’ (PRRs: FAERS = 35.9; VigiBase = 60.3), ‘Hepatitis’ (PRRs: FAERS = 9.76;
VigiBase = 2.9), and ‘Hepatotoxicity’ (PRRs: FAERS = 4.65; VigiBase = 7.73)
• ‘Pneumonitis’ (PRRs: FAERS = 21.44; VigiBase = 37.14)
• ‘Myasthenia gravis’ (PRR: FAERS = 21.46)
• ‘Type 1 diabetes mellitus’ (PRRs: FAERS = 18.63; VigiBase = 34.90) and ‘Diabetic ketoacidosis’
(PRRs: FAERS = 4.3; VigiBase = 9.4)
• ‘Uveitis’ (PRRs: FAERS = 15.51; VigiBase = 35.22)
• ‘Myocarditis’ (PRR: FAERS = 12.54)
• ‘Myositis’ (PRR: FAERS = 10.23)
• ‘Tubulointerstitial nephritis’ (PRRs: FAERS = 5.66; VigiBase = 7.69)
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Table 1. Frequent MedDRA preferred term (PT) reactions (level 4 terms) mentioned in both PembroM
cohorts. All observations listed are statistically significant, with p-value <0.05.
Reaction PT Name 1
FAERS (PembroM Cohort) VigiBase (PembroM Cohort)
AEs % Cohort PRR AEs % Cohort PRR
Alanine aminotransferase increased 26 1.13 2.59p 23 0.92 2.58p
Anaemia 2 52 2.27 1.97p 47 1.87 2.18p
Arthralgia 2 75 3.27 1.69p 81 3.23 2.18p
Arthritis 16 0.69 1.75 19 0.76 2.76
Aspartate aminotransferase increased 27 1.18 2.99p 22 0.88 3.01p
Autoimmune hepatitis 2 + 27 1.18 35.83p 23 0.92 60.29p
Blood bilirubin increased 12 0.52 2.61 11 0.44 3.96
Colitis + 47 2.05 13.09p 60 2.39 22.12p
Constipation 37 1.62 1.59 44 1.76 1.95p
Decreased appetite 2 53 2.3 1.83p 70 2.79 2.71p
Diabetes mellitus 22 0.96 1.87 16 0.64 2.35
Diabetic ketoacidosis + 11 0.48 4.29p 14 0.56 9.41p
Diarrhoea 2 104 4.54 1.53p 129 5.15 1.78p
Dry mouth 18 0.79 1.71 22 0.88 1.56
Dry skin 13 0.57 1.98 15 0.59 2.97
Dyspnoea exertional + 11 0.48 3.01 17 0.68 8.82p
Fatigue 2 202 8.82 2.42p 248 9.89 3.80p
General physical health deterioration + 25 1.09 2.09 26 1.04 5.05p
Hepatic enzyme increased 15 0.65 2.02 19 0.76 2.39
Hepatitis + 33 1.44 9.76p 20 0.79 2.89p
Hepatotoxicity + 10 0.44 4.65p 10 0.39 7.73p
Hyperglycaemia 16 0.69 3.11p 18 0.72 3.20p
Hyperthyroidism + 11 0.48 7.16p 38 1.52 23.94p
Hyponatraemia 31 1.35 4.20p 27 1.08 3.92p
Hypophysitis 2 + 34 1.48 267.83p 26 1.04 308.83p
Hypothyroidism 2 + 41 1.79 11.22p 74 2.95 30.35p
Interstitial lung disease 20 0.87 3.74p 16 0.64 4.61p
Lung disorder + 15 0.65 2.61 14 0.56 5.13p
Lymphadenopathy 12 0.52 2.58 15 0.59 2.54
Muscular weakness 30 1.31 1.95 30 1.19 2.51p
Myalgia 33 1.44 1.47 43 1.72 1.41
Pancreatitis 18 0.79 2.14 16 0.64 2.59
Pemphigoid 2 + 14 0.61 25.48p 23 0.92 53.54p
Pleural effusion 17 0.74 1.95 19 0.76 4.29p
Pneumonitis 2 + 54 2.36 21.44p 68 2.71 37.14p
Rhabdomyolysis 12 0.52 1.99 10 0.39 2.21
Thyroid disorder + 10 0.44 5.38p 10 0.39 9.46p
Thyroiditis 2 + 10 0.44 42.42p 17 0.68 81.45p
Tubulointerstitial nephritis + 10 0.44 5.66p 10 0.39 7.69p
Type 1 diabetes mellitus + 16 0.69 18.63p 17 0.68 34.90p
Uveitis + 15 0.65 15.51p 25 0.99 35.22p
Vitiligo 2 + 26 1.13 166.64p 84 3.35 373.84p
1 PTs are alphabetically sorted. Listed are only those PTs that are mentioned in both FAERS and VigiBase PembroM
cohorts, reported in more than ten AEs in each, and with PRR > 1 in both cohorts. For this reason, similar reactions
reported with different PTs in the two cohorts are not included, despite their statistical strength. Such examples
include PTs like ‘Asthenia’, ‘Autoimmune colitis’, ‘Hypopituitarism’, ‘Myasthenia gravis’, ‘Myocarditis’, ‘Myositis’,
‘Pyrexia’, ‘Pruritus’, ‘Rash’, ‘Rash generalized’, ‘Renal failure acute’, etc. 2 Underlined results highlight the six
highest values, per metric and set. + Indicates PRR > 5 in either cohort. Subscript p denotes 0.0001 ≥ p-value >
0.00001 while subscript p refers to p-values ≤ 0.00001.
Cancers 2020, 12, 1008 9 of 15
Table 2. Most frequently MedDRA preferred term (PT) reactions (level 4 terms) reported with
Pembrolizumab in Melanoma. All observations listed are statistically significant, with p-Value < 0.05.
Organ/System Class 1 Reaction PT Name (whether FAERS and/or VigiBase PembroM cohort) 2
Brain, neurologic ‘Cerebral haemorrhage’ F, ‘Myasthenia gravis’ F
Cardiac ‘Myocarditis’ F
Endocrine
‘Adrenal insufficiency’ FV, ‘Hyperglycaemia’ FV, ‘Hyperthyroidism’ FV,
‘Hypophysitis’ FV, ‘Hypopituitarism’ F, ‘Hypothyroidism’ FV, ‘Thyroid disorder’
FV, ‘Thyroiditis’ FV, ‘Diabetes mellitus’ FV, ‘Diabetic ketoacidosis’ FV, ‘Type 1
diabetes mellitus’ FV
Gastrointestinal ‘Autoimmune colitis’
V, ‘Colitis’ FV, ‘Constipation’ FV, ‘Diarrhoea’ FV,
‘Dry mouth’ FV
Hematologic, vascular ‘Anaemia’ FV, ‘Eosinophilia’ F, ‘Peripheral swelling’ V
Kidney, renal ‘Acute kidney injury’
V, ‘Blood creatinine increased’ V, ‘Renal failure acute’ F,
‘Tubulointerstitial nephritis’ FV
Liver, hepatic
‘Alanine aminotransferase increased’ FV, ‘Aspartate aminotransferase increased’
FV, ‘Autoimmune hepatitis’ FV, ‘Hepatic enzyme increased’ FV, ‘Hepatitis’ FV,
‘Hepatocellular injury’ V, ‘Hepatotoxicity’ FV, ‘Transaminases increased’ V
Lymphadenopathies ‘Lymphadenopathy’ FV
Musculoskeletal ‘Arthralgia’
FV, ‘Arthritis’ FV, ‘Muscular weakness’ FV, ‘Myalgia’ FV, ‘Myositis’ F,
‘Rhabdomyolysis’ FV
Opthalmologic ‘Uveitis’ FV
Pancreatic ‘Lipase increased’ V, ‘Pancreatitis’ FV
Respiratory, pulmonary ‘Cough’
V, ‘Dyspnoea exertional’ FV, ‘Interstitial lung disease’ FV, ‘Lung disorder’
FV, ‘Pleural effusion’ FV, ‘Pneumonitis’ FV, ‘Pulmonary embolism’ V
Skin ‘Dry skin’
FV, ‘Eczema’ V,’Pemphigoid’ FV, ‘Pruritus’ F, ‘Psoriasis’ V, ‘Rash’ F,
‘Rash erythematous’ F, ‘Rash generalised’ V, ‘Rash maculo-papular’ F, ‘Vitiligo’ FV
1 Results are presented in alphabetical order of organ/system group. 2 Reaction MedDRA PT names are listed
in alphabetical order. Superscript symbols F, V, and FV denote FAERS, VigiBase, and both FAERS and VigiBase
PembroM cohorts, respectively. The table contains reaction PTs that have PRR > 1, that are statistically significant,
and that occur in at least ten AEs of the respective cohort.
Our analysis captured, in addition, some other reactions that referred to general patient conditions
or that were more difficult to classify. These include ‘Asthenia’ (VigiBase), ‘Decreased appetite’
(FAERS, VigiBase), ‘Dehydration’ (VigiBase), ‘Fatigue’ (FAERS, VigiBase), ‘General physical health
deterioration’ (FAERS, VigiBase), ‘Pyrexia’ (FAERS), ‘Sepsis’ (VigiBase), ‘Weight decreased’ (VigiBase).
Infections, inflammations and related side effects such as pyrexia or eczema were ambiguous as they
could be either symptoms of an infusion reaction or signs of an infection, as well as ‘Blood bilirubin
increased’ (FAERS, VigiBase) and ‘Hyponatraemia’ (FAERS, VigiBase) might represent both hepatic
and/or hematologic effects.
We also observed that some irAEs occur in absolute numbers more frequently in women, such as
arthritis, pancreatitis, pneumonitis, uveitis, vitiligo, autoimmune colitis, or hyperthyroidism. However,
the examined PembroM cohorts contained more male patient cases, AEs with several missing values,
and the data were not normalized in this respect.
3.3. Comparison of Pembrolizumab, Ipilimumab and Nivolumab Monotherapies in Melanoma
We isolated the AEs of melanoma patients from FAERS and VigiBase that reported only
Pembrolizumab and no other drugs (cohorts named ‘Pembrolizumab (alone)’), and compared them with
results from similar Ipilimumab and Nivolumab cohorts of previous studies. Table 3 contrasts reaction
PTs mentioned in more than 1% of the FAERS ‘Pembrolizumab (alone)’ cohort with summarized
FAERS data for Ipilimumab (2704 AEs) and Nivolumab (890 AEs) in melanoma [33].
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Table 3. Summary of adverse reactions reported in FAERS for Melanoma patients treated with
Pembrolizumab alone, or with Ipilimumab or Nivolumab only. The table contrasts frequent reactions
in these cohorts—full datasets are available as supplementary files (see also [33]). Superscript numbers
in parentheses indicate respective PRR values from each FAERS cohort; all values presented are
statistically significant.
Category/Class Pembrolizumab (alone) 1 Ipilimumab (alone) 2 Nivolumab (alone) 2
Adrenal (+) Adrenal insufficiency (42.38) Adrenal insufficiency (27.29)
Blood 3
Anaemia
Hyponatremia (3.54)
Anaemia (1.48)
Hyponatremia (4.02)
(+)
Febrile Pyrexia Pyrexia (2.03) (+)
Gastrointestinal 3 Colitis
(10.45)
Diarrhoea
Colitis (72.05)
Diarrhoea (4.85)
Intestinal Perforation (10.74)
Colitis (12.88)
Diarrhoea (1.44)
Hepatic (+) Hepatitis (9.02)
Hepatic function abnormal
(8.45)
Liver disorder (3.93)
Hypothalamic Hypophysitis (210.73) Hypophysitis (1051.12) (+)
Opthalmologic 3 (+) (+) Uveitis (26.59)
Renal (+) Renal Failure Acute (1.97) Acute Kidney Injury (2.27)
Respiratory Pneumonitis (18.11) Pneumonitis (11.07) Pneumonitis (16.28)
Skin 3 Pruritus
(1.77)
Rash (1.69)
Pruritus (1.85)
Rash (3.29)
Leukoderma (2439.24)
Pruritus (2.07)
Thyroid 3 Hypothyroidism (8.48) Hypothyroidism (7.88) Hypothyroidism (29.59)
Other
Arthralgia (1.51)
Decreased Appetite (1.58)
Constipation
Myalgia
Decreased Appetite (2.49)
Dehydration (3.43)
Sepsis (2.22)
Decreased Appetite (2.15)
Infusion Related Reaction
(4.41)
Sepsis (1.95)
1 MedDRA preferred terms (PTs) of reactions reported in more than 1% of the FAERS ‘Pembrolizumab (alone)’ cohort’s
AEs; the following terms were excluded: ‘Malignant neoplasm progression’, ‘Death’, ‘Fatigue’, ‘Adverse event’,
‘Nausea’, ‘Disease progression’, ‘Drug ineffective’, ‘Headache’, ‘Dyspnoea’, ‘Asthenia’, ‘Pain’, ‘Vomiting’, ‘Weight
decreased’, ‘Metastatic malignant melanoma’, ‘Malaise’; PTs without PRR scores noted represent non-statistically
significant observations (i.e., with p > 0.05). 2 Data adapted from the results of Figure 3 of [33]; original names of
respective cohorts were ‘Ipilimumab (only)’ and ‘Nivolumab (only)’. 3 The VigiBase ‘Pembrolizumab (alone)’ cohort
reported ‘Anemia’ (PRR: 1.68; p < 0.05), ‘Colitis’ (PRR: 18.9; p < 0.05), ‘Diarrhoea’ (PRR: 1.37; p < 0.05), ‘Uveitis’
(PRR: 36.12; p < 0.05), ‘Vitiligo’ (PRR: 452.34; p < 0.05), and ’ Hyperthyroidism’ (PRR: 28.52; p < 0.05) in more than
1% of its AEs. (+) For additional reaction terms occurring in each cohort’s cases, see respective Supplementary Files.
However, Table 3 should not serve as a direct comparison due to relative differences such as the
number of reactions reported in each cohort, as well as the reduced number of occurrences observed
for each agent-reaction combination in those smaller cohorts. Additional information for all reactions
reported in these cohorts can be found in our supplementary files and in that of [33].
Therefore, Table 3 lists only key reactions for the ‘Ipilimumab (alone)’ and ‘Nivolumab (alone)’
cohorts, extracted from [33]. Furthermore, Table 3 does not mention all reactions observed for
each category and therefore ‘empty’ cells (with no terms) do not necessarily represent absence of
respective phenotypes from a cohort, but rather an occurrence in less than 1% of that cohort’s cases,
or non-statistically significant observations. In addition, our arbitrary cut-off threshold of one percent
for each cohort’s size refers to a different amount of cases every time. In turn, the terms ‘Hypophysitis’
and ‘Hyponatremia’, for example, are not mentioned for the ‘Nivolumab (alone)’ cohort (despite their
statistically significant PRR signals 114.42 and 2.44, respectively) because they were reported in less than
one percent of its cases, while ‘Anaemia’ (occurring in > 1% of its cases, with PRR 1.17) was not found to
be statistically significant. Similarly, the term ‘Uveitis’ is not listed for the ‘Ipilimumab (alone)’ cohort
(with statistically significant PRR value of 12.26) as it was mentioned in less than one percent of this
cohort’s cases. Accordingly, for the FAERS ‘Pembrolizumab (alone)’ cohort, there are reactions reported
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in < 1% of its cases that are related to adrenal insufficiency and (autoimmune) hepatitis conditions,
for example. Last, Table 3 highlights also some observations from the VigiBase ‘Pembrolizumab (alone)’
cohort denoting signal variations between the two (FAERS and VigiBase) ‘Pembrolizumab (alone)’
cohorts attributed to differences in the two data sets’ contents and release dates.
Overall, the three ICIs have both related side effects but also distinct profiles with adrenal, blood,
gastrointestinal, hepatic, hypothalamic, renal, respiratory, skin and thyroid dysfunctions being the
main safety concerns.
4. Discussion
To examine the safety of Pembrolizumab in the treatment of melanoma, we reviewed patient safety
data extracted from AE repositories. Ongoing clinical trials on Pembrolizumab are on a par with other
ICI studies that investigate novel combination therapies and strategies or focus on more specific settings,
such as on poor prognosis groups or on refractory metastatic patients [34]. However, the prognostic
and/or predictive value of numerous immunotherapy biomarker candidates has not been systematically
validated yet in prospective clinical trials, and their utility for guiding a treatment decision needs
further investigations. Moreover, one key aspect during ICI therapy monitoring involves the early
identification and management of the—sometimes, irreversible—irAEs. As molecular biomarkers for
irAEs are also limited, it is unclear how to deal with potential patient characteristics or findings, and
several efforts focus on summarizing ICI toxicities and on developing guidelines for the management
of irAEs (e.g., [15,20,24]). Knowing more about potential risk factors and being aware of the types
of AEs associated with specific ICIs might help to more efficiently recognize and treat irAEs. This is
of great importance considering the results of a recent study in mice xenografted with human colon
cancer cells, suggesting that tumor necrosis factor (TNF) inhibition combined with CTLA-4 and PD-1
immunotherapy may provide a clinically feasible prophylactic strategy regarding some irAEs [35,36].
One other aspect pertaining to irAEs is that their emergence has been suggested to correlate with
clinical benefit to the immunotherapeutic agents, implying a potential predictive role for response to ICI
treatment [37–39]. This is particularly important considering the limited number of both biomarkers
with definitive predictive value in melanoma immunotherapy and alternative treatment options in the
malignancy. However, further studies are needed to confirm this, highlighting the importance of AE
profiling efforts based on evidence from real world event observations.
We therefore processed publicly available AE cases to extract reactions of melanoma patients
treated with Pembrolizumab (Tables 1 and 2) and compared with respective toxicity profiles of
Nivolumab and Ipilimumab from FAERS (Table 3). Our analysis includes real world events and
provides additional insight to previous safety profiling efforts that were based on translational studies,
clinical trials, and meta-analyses. Our results also provide an update to similar AE-based studies that
confirmed known safety considerations [23,40]. Last, our work is an advance over previous studies in
that it examined Pembrolizumab AEs for more melanoma patients, and in that it considered AE cases
extracted from different spontaneous AE repositories (FAERS and VigiBase).
We detected irAEs that affect a variety of organs/systems, including endocrine, dermatologic,
gastrointestinal, hepatic, pulmonary, neurological, cardiac, renal, hematologic and musculoskeletal
complications, as well as infusion/infection reactions. Comparing Pembrolizumab’s FAERS AE profile
in melanoma with those of Nivolumab and Ipilimumab showed that, despite their somewhat distinct
profile, Pembrolizumab and Nivolumab were more similar to each other than to Ipilimumab. For
example, colitis, hypophysitis and rash were reported in larger proportions of the Ipilimumab cohort,
while pneumonitis, hypothyroidism, arthralgia or vitiligos were reported more frequently with
Pembrolizumab or Nivolumab. This finding is in line with results of clinical trials and is supported by
the similar mechanism of action of these agents as PD-1 inhibitors, compared to that of the CTLA-4
inhibitor Ipilimumab [41].
In our PembroM AE datasets from FAERS and VigiBase, several co-medications, which have been
plausibly used for the treatments of side effects or the prevention of AE conditions, were reported.
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For example, antihistamines were most likely prescribed to alleviate rash or pruritus. This information
is also captured by several of the drugs’ indications that reflected AE reactions. Characteristically,
while the most frequent Anatomical Therapeutic Chemical (ATC) Classification System category of
level 2 (i.e., pharmacological or therapeutic subgroup) by number of PembroM FAERS cases was
‘analgesics’, mentioned in 15.58% cases (357 AEs) of this cohort, the top level 2 ATC class by PRR
score was ‘thyroid therapy’ mentioned in 6.98% cases (160 AEs). However, without knowledge of the
patients’ prior history, no robust conclusions can be drawn regarding incidence or potential interactions
between Pembrolizumab and these medications. Nevertheless, with approximately 40% of reports
containing co-medication information, the PembroM cohorts provide a useful dataset for performing
comparative co-administration analyses and the generation of drug interaction hypotheses, particularly
in the context of other co-morbidities. However, we did not pursue this direction further, due to the
reduced numbers of such AEs contained in the examined PembroM cohorts, though we believe that
this will improve over time as more reports become available. Furthermore, a few cases reported
also the administration of Nivolumab or Ipilimumab. The reporting of these two immunotherapeutic
agents most likely represents a therapy switch between the different ICI treatments, since the only ICI
combination approved by the US FDA for the treatment of advanced melanoma is that of Ipilimumab
plus Nivolumab.
It is important to note here that our results should not be interpreted as calculated incidences in
the general melanoma patient population, as the reported frequencies represent occurrence in patients
who manifested AEs during therapy and their incidence was reported. This is also not the intended
use of data coming from spontaneous AE repositories since they contain only AEs and are therefore
biased without proper normalization considering reference/control data.
Moreover, there is a number of parameters of high clinical significance that would additionally
benefit our study and the assessment of ICI pharmaceuticals [42]. However, we could not consider
data that are neither available nor straightforward to extract from public AE repositories. Some such
factors that could not be yielded for our analysis include detailed patient/event history (including
treatment duration, timing, dosage or previous therapies and co-morbidities), the setting in which
the treatment took place (e.g., first-line systemic treatment in patients with unresectable melanoma or
adjuvant treatment after tumor resection), patient Karnofsky scores or Eastern Cooperative Oncology
Group (ECOG) performance status, the duration of irAEs, or specific AE severity grading.
One other major issue related to irAEs is the medical costs associated with them. In this context,
up-to-date knowledge about these side effects remains a critical issue for the healthcare system, as well
as for many patients who might suffer poorer quality-of-life without any tangible clinical benefit from
specific drug treatment(s). Adoption of integrated safety assessment and interpretation techniques is
potentially a key factor to help understand better the landscape underlying such economic costs of AEs
associated with ICIs, providing the opportunity to shift the tradeoff between AE costs and the clinical
benefit derived from the use of these agents towards the best for patients and for the community.
Computational AE analytics provide informative clinical insights for this goal and an augmented
resource for the systematic characterization of safety considerations (e.g., [33,43,44]), especially when
combined with additional data dimensions such as molecular parameters (e.g., [30,45–47]). As more
real world data emerges we anticipate future directions to include characterization of data from more
AERS (e.g., EudraVigilance), more informed prospective therapy studies, improved irAE diagnosis and
characterization methods, investigation of tumour-dependent irAE profiles, and identification of patient
subgroups with little benefit from ICI therapy so as to avoid unnecessary irAE occurrence. Our results
thus provide important additional insights to support the current global efforts to characterize the
utility and safety of Pembrolizumab in melanoma.
5. Conclusions
Based on evidence extracted from the public FAERS and VigiBase repositories, we inspected two sets
of AEs, each with more than two thousand melanoma patients treated with Pembrolizumab. Our results
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confirm known toxicological considerations for this, and other widely used, immunotherapeutic agents’
related and distinct side-effect profiles, and identify specific immune-related reactions from different
organs and systems as well as infusion/infection reactions. Our study provides additional insight to the
profiling efforts of ICIs and we expect that AE awareness and knowledge on potential risk factors will
help in the early recognition and informed management of irAEs in melanoma patients treated with ICIs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/4/1008/s1,
Supplementary file: Summarized views of the examined adverse event cohorts.
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